Share price · MESO
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when MESO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 29 Oct 2026+17.0%
- 19 Oct 2026-10.0%
- Day beforeMesoblast: 6-K filing
- 27 Aug 2026+8.0%
- 17 Aug 2026+9.1%
- 15 Jul 2026+9.0%
- 13 Jul 2026+5.1%
- Day beforeMesoblast: 6-K filing
- 26 Jun 2026-9.0%
- Day beforeMesoblast: 6-K filing
- 25 Jun 2026-6.8%
- 7 Apr 2026-7.9%
Nothing announced by MESO that day or the session before.
- 5 Mar 2026+7.5%
Nothing announced by MESO that day or the session before.
Share of unusual movement by asset
For each asset, the share of MESO's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
rexlemestrocel-Levents and moves
| 2 | shown from 8 days |
remestemcel-L (Ryoncil)events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 12% |
| Other company news (earnings, financing, releases naming no asset) | — | 43% |
| Sessions with no dated event | — | 45% |
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
remestemcel-L(Ryoncil) | Approved | Allogeneic MSC therapyCell therapy | Inflammatory Bowel DiseaseGraft-versus-Host Disease Ulcerative Colitis, Crohn's Disease |
| Phase 3 | Mesenchymal precursor cells (MPCs)Cell therapy | Heart FailureChronic Low Back Pain |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (7)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| FY2026-Q3 | $30M | — | $122M | $4.1M | report ↗ |
View 6 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2023-Q1 | $1.9M | $7.1M | $49M | $19M-$16M operating cash flow | report ↗ |
| 2022-Q4 | $2.1M | $7.7M | $68M | $24M-$16M operating cash flow | report ↗ |
| 2022-Q3 | $1.5M | $5.7M | $86M | $17M-$14M operating cash flow | report ↗ |
| 2022-Q1 | $2.0M | $8.3M | $77M | $21M-$15M operating cash flow | report ↗ |
| 2021-Q4 | $2.4M | $10M | $95M | $26M-$17M operating cash flow | report ↗ |
| 2021-Q3 | $3.6M | $9.3M | $116M | $23M-$20M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $17M | $35M | $162M | $26M-$50M operating cash flow | report ↗ |
Mesoblast reported revenue of $17.2M for fiscal year 2025, up 191.5% YoY, with R&D spend of $34.81M, up 37.3% YoY. Cash and equivalents stood at $161.55M, and the company reported a net loss of $102.14M, with a quarterly net burn of $102.14M.
Insider transactions
Open-market activity, trailing 12 months: 30 purchases ($37.5M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-04-10 | George Gregory · director, 10% owner | Open-market purchase | 2,324,072 | $1.48 | $3.4M | Form 4 |
| 2026-04-10 | George Gregory · director, 10% owner | Open-market purchase | 2,324,072 | $1.48 | $3.4M | Form 4 |
| 2026-04-09 | George Gregory · director, 10% owner | Open-market purchase | 886,890 | $1.43 | $1.3M | Form 4 |
| 2026-04-09 | George Gregory · director, 10% owner | Open-market purchase | 105,000 | $1.46 | $153K | Form 4 |
| 2026-04-09 | George Gregory · director, 10% owner | Open-market purchase | 500,000 | $1.44 | $720K | Form 4 |
| 2026-04-09 | George Gregory · director, 10% owner | Open-market purchase | 10,000 | $1.44 | $14K | Form 4 |
| 2026-04-09 | George Gregory · director, 10% owner | Open-market purchase | 4,760 | $1.44 | $7K | Form 4 |
| 2026-04-09 | George Gregory · director, 10% owner | Open-market purchase | 20,000 | $1.43 | $29K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 68 reporting institutions held 3.3M shares ($49.9M, 2.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 630,855 | $9.7M |
| 2 | MORGAN STANLEY | 514,431 | $7.9M |
| 3 | GOLDMAN SACHS GROUP INC | 397,215 | $6.1M |
| 4 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 386,472 | $5.9M |
| 5 | UBS Group AG | 132,573 | $2.0M |
| 6 | BANK OF AMERICA CORP /DE/ | 100,004 | $1.5M |
| 7 | JANE STREET GROUP, LLC | 98,786 | $1.5M |
| 8 | Penbrook Management LLC | 87,075 | $1.3M |
| 9 | CITADEL ADVISORS LLC | 85,959 | $1.3M |
| 10 | GROUP ONE TRADING LLC | 83,915 | $1.3M |
| 11 | M&G PLC | 59,100 | $887K |
| 12 | LPL Financial LLC | 49,617 | $763K |
| 13 | Rialto Wealth Management, LLC | 46,500 | $715K |
| 14 | LAZARI CAPITAL MANAGEMENT, INC. | 46,121 | $709K |
| 15 | Fi3 FINANCIAL ADVISORS, LLC | 42,015 | $646K |